Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.

Journal of experimental & clinical cancer research : CR - 30 Jan 2026

Ye Wu, Wu Xia, Tang Yuqian, Zhang Ying, Du Yiwen, Yang Kun, Yang Yankun, Gong Yuping

Abstract excerpt

BACKGROUND: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled growth of immature myeloid cells, often with a poor prognosis due to therapy resistance. This study investigated the prognostic significance of SRSF2 mutations in AML and their impact on chemotherapeutic drug sensitivity. METHODS: The prognostic value of SRSF2 mutations was analyzed in AML patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Daunorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Prognosis

Share to Serine-Arginine Splicing Factors

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41618430
DOI: 10.1186/s13046-026-03649-y
PMCID: PMC12973616

Genes

SRSF2
THBS1
PDGFB
CP
ETV7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.PMID 41618430Read ↗

Sensitivity to ATR–CHK1 pathway inhibition in AML/MDS is enhanced by <i>SRSF2</i> mutations and reduced by RUNX1 lossSemantic proximity Read ↗

Sequence-dependent splicing dysregulation drives therapy resistance in pediatric AML.Semantic proximity Read ↗

Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasmsSemantic proximity Read ↗

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity Read ↗

Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.Semantic proximity Read ↗

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemiaSemantic proximity Read ↗

Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.Semantic proximity Read ↗

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.Semantic proximity Read ↗

Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice.Semantic proximity Read ↗

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.Semantic proximity Read ↗

Comprehensive Analyses of the Effects of the Small-Molecule Inhibitor of the UHM Domain in the Splicing Factor U2AF1 in Leukemia CellsSemantic proximity Read ↗

Myeloid Disease Mutations of Splicing Factor SRSF2 Cause G2-M Arrest and Skewed Differentiation of Human Hematopoietic Stem and Progenitor Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.